Vizsgálati helyszín
Crystal Comfort S.R.O.
Vranov nad Topľou, Presov 093 01, SzlovákiaEU-13 felzárkózó országMég nincs intézményhez kötve
- 17futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis11 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Toboroz14 vizsgálat
- Lezárult10 vizsgálat
- Még nem toboroz2 vizsgálat
- Fut, nem toboroz1 vizsgálat
- Fő szponzor
- Intra-Cellular Therapies, Inc.3 vizsgálat
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company3 vizsgálat
- Neurocrine Biosciences3 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- MapLight Therapeutics2 vizsgálat
- és még 12
Futó vizsgálatok
Meghívásos bevonás
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660· 2. fázis· MapLight Therapeutics· Forrás
Toboroz
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472· 2/3. fázis· Exciva GmbH· Forrás
Meghívásos bevonás
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700· 2. fázis· Seaport Therapeutics· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192· 2. fázis· MapLight Therapeutics· Forrás
Toboroz
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· 2. fázis· Intra-Cellular Therapies Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240· 2. fázis· Seaport Therapeutics· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Contact: Dagmar Breznoscakova, Site 4403
Toboroz
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
2023-507372-42-00· 2. fázis· Oryzon Genomics S.A.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
2024-513104-34-00· 2. fázis· HMNC Holding GmbH· Forrás
Lezárult
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· 3. fázis· Neurocrine Biosciences Inc.· Forrás
Lezárult
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· 3. fázis· Janssen Cilag International· Forrás
Lezárult
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373· 2/3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Lezárult
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157· 3. fázis· Neurocrine Biosciences· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
NCT04464564· 3. fázis· Otsuka Pharmaceutical Development & Commercialization Inc.· Forrás
Lezárult
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
NCT04521478· 2. fázis· Boehringer Ingelheim· Forrás
Hibát jelzek